Prior research has suggested that Liraglutide, an analog of glucagon-like peptide-1, exhibits potential in the treatment of type 2 diabetes and prevention of NASH by inhibiting the activation of the NLRP3 inflammasome (Armstrong et al., 2016; Yu et al., 2019; Ao et al., 2020; Ma et al., 2022). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.